Login to Your Account



China's Zensun seeks $76M to advance heart failure drug Neucardin to the finish line

By Pearl Liu
Staff Writer

Wednesday, January 10, 2018

HONG KONG – Chinese biotech Zensun (Shanghai) Sci & Tech Co. Ltd., which focuses on innovative therapeutics for cardiovascular and energy metabolic diseases, has plans to raise about ¥500 million (US$76 million) from a consortium of investors, including a state-owned fund.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription